knowledge -WSS

knowledge

author：leisure time 2025-08-31 21:00:38 - browse：5

WASHINGTON — Grail is aggressively lobbying to get Medicare to pay for its cancer-screening test Galleri — but experts tell STAT that the company has a far more complicated path to that end than the makers of most medicines or medical devices.

Grail’s controversial blood test Galleri screens for multiple cancers. The Food and Drug Administration has not yet approved it, so Medicare hasn’t had to make a decision on whether to cover it or not. Right now, most people pay for it out of pocket. It runs about $950.

In general, Medicare covers FDA-approved medicines and medical devices that help diagnose or treat disease or injury. But there’s a catch for Grail: Medicare doesn’t cover tests that simply screen healthy people, as Galleri does.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： Congenital heart disease patients face new threat of heart failure

entertainment

WSS

Congenital heart disease patients face new threat of heart failure

Congenital heart disease patients face new threat of heart failure

Leukemia patients are helped by Syndax's new type of therapy

Chemotherapy shortages won’t get better under Biden’s latest plan

U.K. Biobank has 500,000 peoples' genome sequences available

How to pay for weight loss drugs and save Medicare

hotspot

knowledge

hotspot

23andMe had bad news about my health. I wish a person had delivered it

What to do when lifesaving products contribute to climate change

The cancer drug shortage isn’t new — and neither are the solutions

Leukemia patients are helped by Syndax's new type of therapy

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

After sickle

Hepatitis C has a cure — but many Americans still lack access to it

Patients' immediate access to test results puts radiologists in a bind

Drug repurposing or repositioning? The language matters

Disappointing trial forces Pfizer to pivot on obesity medicine plans

Wikipedia

Despite FDA concern, risk that CAR

FDA investigates CAR

FDA investigates CAR

How to pay for weight loss drugs and save Medicare

Despite FDA concern, risk that CAR

Radiology is caught between AI's potential and concern for patients

leisure time

entertainment

focus

focus